tACS Connectivity Trial in Early Alzheimer's

🧫 Experiment Protocol ClinicalAlzheimer's DiseaseBDNF/CACNA1G/HCN1humanproposed

# tACS Connectivity Trial in Early Alzheimer's ## Background and Rationale Alzheimer's disease progression follows a network-based model where pathological tau propagates along functional connectivity pathways. Recent evidence demonstrates that hyperconnected brain regions serve as hubs for early tau accumulation, creating a self-reinforcing cycle where elevated connectivity accelerates pathological spread, which in turn drives further hyperconnectivity. This pathophysiological mechanism suggests that normalizing network synchronization could interrupt the disease cascade independent of traditional amyloid-targeting approaches. Transcranial alternating current stimulation (tACS) offers a non-invasive method to modulate neural oscillations and functional connectivity with high temporal precision. This randomized, double-blind, sham-controlled trial will investigate whether targeted tACS intervention can normalize aberrant connectivity patterns in early-stage Alzheimer's disease patients. The study employs a novel personalized approach using baseline fMRI connectivity mapping to identify hyperconnected regions for individualized stimulation targeting. Primary measurements include resting-state functional connectivity assessed via fMRI, cognitive performance batteries, and tau PET imaging to quantify pathological burden. Secondary outcomes encompass EEG-derived connectivity metrics, cerebrospinal fluid biomarkers, and quality of life measures. The intervention protocol delivers gamma-frequency (40 Hz) tACS to identified hyperconnected nodes over 12 weeks, with stimulation parameters optimized based on individual network topology. This represents the first targeted neuromodulation trial specifically designed to interrupt tau propagation pathways in Alzheimer's disease. The approach's innovation lies in its network-informed targeting strategy and focus on connectivity normalization rather than symptom management. Success could establish a new therapeutic paradigm for early Alzheimer's intervention, potentially slowing disease progression through direct modulation of pathological network dynamics. This experiment directly tests predictions arising from the following hypotheses: - **Gamma entrainment therapy to restore hippocampal-cortical synchrony** - **Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation** - **Prefrontal sensory gating circuit restoration via PV interneuron enhancement** - **Sleep Spindle-Synaptic Plasticity Enhancement** - **HCN1-Mediated Resonance Frequency Stabilization Therapy** ## Experimental Protocol Phase 1 (Weeks -4 to 0): Comprehensive screening including neuropsychological assessment (ADAS-Cog, MoCA), structural/functional MRI acquisition, tau PET imaging, and CSF biomarker collection (n=120 early AD patients, n=40 healthy controls). Individual connectivity matrices generated using seed-based analysis targeting default mode and salience networks. Phase 2 (Week 0): Randomization to active tACS (n=60) or sham stimulation (n=60) groups using computer-generated sequences. Baseline EEG recording during resting state and cognitive tasks. Phase 3 (Weeks 1-12): Intervention delivery using personalized montages targeting hyperconnected regions identified in Phase 1. Active group receives 40 Hz sinusoidal stimulation at 2 mA peak-to-peak intensity, 20-minute sessions, 5 days/week. Sham group receives identical setup with 30-second ramp-up/down only. Weekly safety assessments and adherence monitoring. Phase 4 (Weeks 4, 8, 12): Interim assessments including cognitive testing, EEG connectivity measures, and adverse event documentation. Phase 5 (Week 12): Primary endpoint evaluation with repeat fMRI, tau PET, cognitive batteries, and biomarker collection. Phase 6 (Weeks 16, 24): Follow-up assessments to evaluate intervention durability. Statistical analysis employs mixed-effects models accounting for baseline connectivity patterns, with significance threshold p<0.05 corrected for multiple comparisons using false discovery rate. ## Expected Outcomes - 1. Significant reduction in aberrant functional connectivity within targeted networks, with effect size Cohen's d ≥ 0.6 compared to sham group (p<0.01) - 2. Cognitive stabilization measured by <2-point decline on ADAS-Cog versus expected 4-6 point decline in sham group over 12 weeks - 3. Reduced tau accumulation rate of 15-25% in targeted brain regions compared to sham group, assessed via standardized uptake value ratios - 4. Normalization of gamma-band coherence patterns with 20-30% improvement in network efficiency metrics derived from EEG analysis - 5. CSF biomarker changes showing 10-20% reduction in phosphorylated tau levels and stabilized neurofilament light concentrations - 6. Sustained treatment effects lasting 12 weeks post-intervention, with 60-70% of connectivity improvements maintained at follow-up ## Success Criteria - • Primary efficacy: ≥0.5 effect size reduction in target network hyperconnectivity with p<0.05 significance versus sham - • Cognitive preservation: <50% of expected cognitive decline rate compared to natural history data and sham group - • Safety threshold: <10% serious adverse events directly attributable to stimulation with no lasting neurological sequelae - • Biomarker response: Statistically significant reduction in tau PET signal within stimulated regions (p<0.05) - • Durability requirement: ≥50% of connectivity improvements maintained at 3-month follow-up assessment - • Protocol feasibility: ≥85% completion rate for stimulation sessions with <20% dropout rate across study duration

Source: wiki

🧫 Experiment Extras

🔴 Alzheimer's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found